Launch of new unique needle

Launch of new unique needle

Vitrolife launched a new needle for the collection of human oocytes at ESHRE,
the largest congress of the year within IVF. 
“The needle combines the good properties of our previous needles with a new way
of designing the front part and tip, so that the patient will experience less
discomfort. We are extremely happy about the positive response and attention
that this needle received at the congress,” says Nils Sellbom, Sales Director at
Vitrolife. 


At the annual European reproduction congress ESHRE in the beginning of July a
new needle, Swemed Sense™, was launched. The needle is designed with a thinner
front part and tip so as to minimize tissue damage, bleeding and pain. As the
body of the needle has a larger diameter, the ability to collect the oocytes
from the woman is not reduced, however. The procedure is just as fast as when a
thicker needle is used. A patent application has been submitted for Swemed
Sense™. It is estimated that the market for needles used in follicle aspiration
to collect oocytes for IVF amounts to approximately 50 million Euros.




July 14, 2008
Kungsbacka, Sweden 

Magnus Nilsson
CEO








Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.